Chimeric antigen receptor (CAR) T cells use re-engineered cell surface receptors to specifically bind to and lyse oncogenic cells. Two clinically approved CAR-T?cell therapies have significant clinical efficacy in treat-ing CD19-positive B cell cancers. With widespread interest...
Other documents